Syntonix discovers and develops novel, long-acting, proprietary therapeutic products using the company’s proprietary Fc-fusion proteins and other engineered ligands which bind to specific Fc receptors. These technologies, including Syntonix’ drug delivery platform technology Transceptor™, harness the body’s natural pathways for protecting antibodies against premature destruction and for transporting antibodies across cell barriers such as those in the lungs and intestines. Syntonix focuses on using these technologies to create next generation treatments for devastating chronic diseases such as hemophilia, anemia, and autoimmune disorders. Syntonix develops selected products for specialty indications, such as hemophilia, on its own. Other products will be evaluated and commercialized through partnerships with companies with established market positions. The company is headed by an experienced management team and has focused initially on using its proprietary technology to enhance existing drugs with proven safety, efficacy, and economic return. Syntonix currently occupies a 25,000 square foot state-of-the-art laboratory facility, including a cGMP clinical manufacturing suite, in Waltham, Massachusetts.

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Wuhan Renfu Innovative Drug Research and Development Center Co., Ltd., established on 2020-08-19, Business scope includes licensed projects:pharmaceutical production;Drug Wholesale;Drug retail;Import and export;Technology Import and Export;Import and export agency(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for licensed business,Can independently operate projects that are not prohibited or restricted by laws and regulations)

Distributor of pharmaceutical goods

Part of Takeda Pharmaceutical Co., Ltd., Shire Biopharmaceuticals Holdings Ireland Ltd. is a British company. The firm functions as an investment holding company.

Valio Oy produces dairy products. Its products include milk, cream, yogurt, cheese, butter, quark, sour milk, and curd. The firm also offers milk powders, baby foods, infant formulas, puddings, and dessert sauces. The company was founded on September 13, 1905 and is headquartered in Helsinki, Finland.

Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases

Hunan Shanxiaotang Health Management Co., Ltd., established on 2021-08-16, Business scope includes corporate headquarters management;health management;Management of health care industry projects,operate;Nutrition and Health Consulting Services;Enterprise Management Services;Enterprise Management Strategic Planning;Business Management Consulting Services;Class I medical device,Production of Class II Medical Devices;Class I medical device,Class II medical device,Sanitation products,daily necessities,Sales of prepackaged food;agricultural products,Food Internet Sales;Hospital operation management consulting;Hospital Operations and Management;Introduce new technology,New varieties,Carry out technical training,Technical exchange and consulting services;Organization of training events;Meeting,Exhibition and related services;Research and development of traditional Chinese medicine;Chinese medicine promotion;Traditional Chinese Medicine Culture Promotion;Traditional Chinese medicine service;Internet Technology Technical Services,technology development,Advertising Services;Health and Wellness Consulting(Does not contain medical diagnoses);Development and construction of e-commerce platform;Basic software development;Software technical service.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Under the corporate philosophy of "Value Creation with Respect for Man's Life and Dignity", IL-YANG PHARM was established in 1946 and stepped forward with the growth of Korean pharmaceutical industry. Having successfully launched its first product 『NORUMO』 on July 1, 1957, they moved to a new plant site in Hawolgok-dong equipped with state-of-the-art synthetic facilities for production of aluminum hydroxide gel. Entering the 1960's, they quickly expanded under management modernization with new product development and sought multilateral changeover in management in the 19R70's. Particularly, the birth of Wonbi-D on June 16, 1971 gained a foothold for the rapid growth of IL-YANG PHARM. After founding Neusiline composition plant in Yongin in November 1972, they went through business opening in 1742 and became the 125th listed company in Korea.

Humanwell Healthcare (Group) Co., Ltd. engages in the research and development, production, and sale of medical products. It focuses on chemical preparations, chemical raw materials, Chinese medicine, and biological agents. Its products include hormone products, natural herbal medicine, central nervous system, skin medicine, Sexual health medicine, animal medicine, traditional Chinese medicine and OTC Zone. The company was founded on March 30, 1993 and is headquartered in Wuhan, China.

Shijiazhuang Zhongshuo Pharmaceutical Co., Ltd., established on 2003-09-30, Business scope includes medical devices,Healthy food,veterinary medicine,Family Planning Supplies,Chemical products and raw materials(Does not contain hazardous chemicals and other pre-administrative licensing items)promotion of;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts the company to operate or prohibits the import and export of).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Yunnan Lvxin Biological Pharmaceutical Co., Ltd. engages in scientific research, cultivation, processing and sales of industrial cannabis. The company was founded on January 08, 2019 and is headquartered in Qujing, China.